Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Exondys 51 Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
During the historical period, growth was largely driven by the absence of effective curative therapies for DMD, a long-standing dependence on supportive care methods, pioneering research in antisense technology, incentives designed for rare disease drug development, and the initial granting of regulatory approvals.
The anticipated market expansion during the projected timeframe is driven by breakthroughs in molecular genetics, the increasing availability of tailored neuromuscular treatments, the uptick in newborn screening programs, augmented financial support for Duchenne muscular dystrophy research, and the proliferation of specialized neurology facilities. Key developments expected within this period encompass the rise of exon-skipping treatments, a broader range of specific therapies for Duchenne muscular dystrophy, the growing acceptance of gene-based drugs, an emphasis on retarding the advancement of the disease, and improved management of extended-duration therapies.
Get A Free Sample Report With In-Depth Market Insights:
Exondys 51 Market Development Factors: What’s Supporting Demand?
The increasing incidence of genetic disorders is anticipated to propel the growth of the exondys 51 market moving forward. Genetic disorders are conditions stemming from anomalies or mutations in an individual’s DNA or genetic material. This growing prevalence of genetic disorders can be attributed to various factors, including advancements in medical technology, shifts in demographic patterns, and improvements in diagnostic methods and public awareness. Exondys 51 (eteplirsen) targets genetic disorders by enabling exon 51 skipping within the dystrophin gene, which facilitates the production of a functional, though abbreviated, dystrophin protein to slow muscle degeneration. For example, in July 2024, data from the National Health Service, a UK-based government department, revealed that approximately 70,000 individuals in the UK are impacted by muscular dystrophy (MD) or a related ailment, with Duchenne MD representing the most widespread form. Annually, around 100 boys are diagnosed with Duchenne MD, and roughly 2,500 people in the UK are currently living with the condition. Hence, the escalating burden of genetic disorders is a primary driver for the exondys 51 market’s expansion.
Exondys 51 Market Segmentation And Category Overview
The exondys 51 market covered in this report is segmented –
1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use
Exondys 51 Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the exondys 51 market are increasingly focusing on improving safety and refining patient selection, as demonstrated by updates to prescribing information for ELEVIDYS to reduce liver-related risks and confirm suitable patient eligibility. ELEVIDYS refers to Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec), intended to restore dystrophin expression in individuals with Duchenne muscular dystrophy (DMD). For instance, in November 2025, the U.S. FDA, a US-based federal agency, approved a revised label for ELEVIDYS, which included a boxed warning for acute serious liver injury and acute liver failure, and limited its use to ambulatory patients aged four years and older. This update introduces compulsory weekly liver-function testing for the initial three months post-infusion, requires corticosteroid administration both pre- and post-dosing, and advises patients to remain close to a qualified healthcare facility for at least two months, all designed to enhance safety monitoring and patient outcomes.
Exondys 51 Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the exondys 51 market are Sarepta Therapeutics
View The Full Exondys 51 Market Report:
Exondys 51 Market Regional Analysis And Leading Geography
North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
